Abstract 175P
Background
Cancer cells evade the human immune system by manipulating the tumor-immune microenvironment (TIME) via suppressing the immuno-activator and promoting the immune-suppressive mediators. Hence, targeting immuno-modulatory factors became an ingenious treatment option, particularly for cancer types that shows scarcity of treatment options such as triple negative breast cancer (TNBC). Novel immuno-modulatory targets such as Galectin (GAL) 3 and 9 have been found to be overexpressed in TNBC, repressing the immune surveillance. Similarly, TNBC tumors were found to prevent the activation of immune infiltrating lymphocytes via overexpressing immune checkpoint CD155 expression on its surface. MHC class I polypeptide–related sequence A (MICA) and MICB are stress-induced ligands essential for innate immunity activation at the TIME. However, their expression is also often suppressed in TNBC, leading to immune suppression and poor prognosis. Our research group has extensively worked on microRNAs to modulate multiple targets simultaneously. Hence, this work unravels the expression profile of the miR-548c in BC tissues, evaluate its unprecedented immunomodulatory role in TNBC via altering GAL3/9, CD155, and MICA/B expression.
Methods
BC female patients (n=20) were recruited. In-silico analysis was used to identify miRNAs that target immunomodulatory targets. MDA-MB-231 TNBC cells were cultured and transfected by oligonucleotides. Total RNA was extracted using Biazol, reverse transcribed and quantified using qRT-PCR.
Results
miRNA-548c is a down-regulated tumor suppressor miRNA in BC tissues compared to its normal counterparts. MiRNA-548c was validated to regulate the immunogenic profile in TNBC. Given the overexpression of the immuno-suppressive GAL3, GAL9, and CD155, miR-548c simultaneously constrained their expression in TNBC cells. Moreover, ectopic expression of miR-548c in MDA-MB-231 cells resulted in a marked upregulation of the expression of the immuno-activators MICA and MICB, enhancing the overall immunogenic profile of TNBC cells.
Conclusions
This study identifies miRNA-548c as a booster of the immune surveillance by concomitant adjustment for the immunogenic ligands expressed/produced by the TNBC cell.
Legal entity responsible for the study
The authors.
Funding
This work was supported by Swiss National Science Foundation (SNSF), grant IZSTZ0_198887.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
60P - Adaptive NK cells as a therapeutic option for childhood leukaemia
Presenter: Zoya Eskandarian
Session: Poster Display
61P - Unlocking the Power of Natural Killer Cells: Precision Selection with Cutting-Edge Microfluidics
Presenter: Neelima KC
Session: Poster Display
63TiP - A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen: MIZAR trial
Presenter: Qing Xu
Session: Poster Display
68P - Real-world (rw) outcomes in patients (pts) with metastatic (m) NSCLC and STK11, KEAP1 and/or KRAS mutations (mut) receiving PD-(L)1-based treatment (tx): CORRELATE
Presenter: Solange Peters
Session: Poster Display
70P - LIST (Lung Initiative on Sequence Therapy), a real-world study of nivolumab for advanced NSCLC in France: first effectiveness, safety, and IO-rechallenge results
Presenter: Benoît GODBERT
Session: Poster Display
72P - Camrelizumab plus apatinib after chemoradiotherapy in unresectable stage III non-small-cell lung cancer?A multi-center, single-arm, phase 2 study
Presenter: Hui Zhouguang
Session: Poster Display
74P - A single-center, Phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
Presenter: Wen Feng Fang
Session: Poster Display
75P - Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation
Presenter: Ana Baramidze
Session: Poster Display